Early clinical trials are already combining vaccines with programmed cell death protein 1 (PD‐1) blockers for treatment of various malignancies including AML.27 The combination of both epigenetic modification by azacytidine and PD‐1 blockade by nivolumab was recently shown to be a safe and effective therapy for relapsed AML.28 However, other checkpoint molecules might be even more relevant as suggested by our preclinical data showing that blockade of lymphocyte activation gene 3 (LAG‐3) strongly enhances DC‐induced immune responses against viral and leukaemia‐associated antigens.29 This evidence concerns the gene LAG3 and leukemia.